Main - NeOnc Technologies Holdings, Inc.

NeOnc's NEO100 is changing lives.

Watch this video featuring two patients using NEO100 who are experiencing remarkable progress. Their positive responses inspire hope and underscore the potential of NEO100.

WATCH VIDEO

NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets

NeOnc expands its IP portfolio strengthening protection for its novel CNS therapeutics and reinforces its position as a leader in brain cancer innovation.

NeOnc Expects Full Enrollment In Phase 2a Trial of NEO100-01

NeOnc nears full enrollment for its Phase 2a clinical trial of NEO100-01, an intranasal therapy targeting aggressive brain cancers. With only six patients left to enroll, read-out data is expected in early 2026. This promising treatment bypasses the blood-brain barrier and has received FDA Orphan Drug and Fast Track designations.

NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company’s New President

NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) announces the SEC’s approval of its Form S-1 registration for a direct listing. Trading on the Nasdaq Global Market begins March 26, 2025. Learn more via EDGAR or NeOnc’s investor relations page at neonctech.com.

Barrier

NeOnc is the developer of a proprietary, patented platform technology that can potentially transport pharma-based therapeutics directly to the brain without the normal boundary restrictions imposed by the body’s Blood-Brain Barrier (BBB). Using NeOnc’s formulations, pharma companies that have limited success with their CNS therapeutics because of current delivery restrictions may be able to provide patients with potentially more effective treatments.

the

Problem

The potential for greater success in treating CNS-based diseases such as Glioblastoma remains limited by the inability to deliver therapeutics directly to the brain.

our

Solution

Our proprietary approaches and patented technologies deliver new therapies for treating brain cancers as well as facilitating the transport of established or new therapeutics across the blood-brain barrier to improve efficacy for the treatment of diseases in the brain.

the

Potential

By providing a regulator for tumor cell growth along with a transport mechanism for therapeutics, plan to provide doctors and health-care professionals with a way to deliver better outcomes for their patients.

LATEST RESEARCH and STUDY

NeOnc maintains an aggressive regimen of research and study into its delivery of therapeutics and formulations to validate and ensure our ability to have an impact on the treatment of CNS-based disease.

EXPLORE OUR RESEARCH

PRESS RELEASES

The following are the latest Press Releases and Announcements regarding NeOnc Technologies Holdings’ advancements. To see all the Press Releases, click HERE